This week in techniques



Licensing status

Publication and contact information


Monitoring response to preventive therapy in patients with Huntington's disease (HD) using 18F-labeled fluorodeoxyglucose PET (FDG-PET) imaging

PET imaging of the brain could help monitor treatment responses in patients with presymptomatic and early symptomatic HD. In two independent cohorts of patients with HD, longitudinal 18F-labeled FDG-PET imaging of multiple brain regions identified a pattern of region-specific increases and decreases in metabolic activity that were not seen in healthy individuals. The pattern intensified over time and correlated with years to onset, an empirical estimate of the time remaining until clinical symptoms of HD appear. Planned work includes validating the method in a two-year observational study of about 1,500 patients with presymptomatic HD.

SciBX 6(37); doi:10.1038/scibx.2013.1045
Published online Sept. 26, 2013

Patent application filed by The Feinstein Institute for Medical Research; unlicensed

Tang, C.C. et al. J. Clin. Invest.; published online Aug. 29, 2013;
Contact: David Eidelberg,
The Feinstein Institute for Medical Research, Manhasset, N.Y.